米非司酮及孕三烯酮用于卵巢子宫内膜异位症腹腔镜术后治疗的临床观察

目的:探讨米非司酮及孕三烯酮用于卵巢子宫内膜异位症腹腔镜术后的疗效。方法:选择因卵巢子宫内膜异位症在该院行腹腔镜术的患者86例,随机分为3组,A组为米非司酮治疗组(30例);B组为孕三烯酮治疗组(30例);C组为单纯腹腔镜手术组(26例)。所有患者随访324个月,观察疗效。结果:米非司酮组有效率为75.9%;孕三烯酮组有效率为79.3%;单纯手术组有效率为58.3%。服药组疗效明显优于单纯手术组(P<0.05),米非司酮组患者副反应明显小于孕三烯酮组。结论:米非司酮用于卵巢子宫内膜异位症术后的治疗,有效、方便、廉价及副反应小,可作为术后药物治疗的选择。

Clinical observation of treatment in ovary endometriosis with Mifepriston and Gestrinone after laparoscopic surgery

Objective:To investigate the role of Mifepriston and Gestrinone in ovary endometriosis after Laparoscopic surgery.Methods:86 women with ovary endometriosis after Laparoscopic surgery were divided into three groups: group A-30 cases in Mifepriston 12.5 mg take orally;group B-30 cases in Gestrinone 2.5 mg take orally;group C-26 cases in Laparoscopic surgery only.All patients were visited 3 to 24 months and observed curative effect.Results: Rates of efficiency was 75.9% in group A.Rates of efficiency was 79.3% in group B.Rates of efficiency was 58.3% in group C.The3 curative effects of both group A and group B were similar significant higher than group C(P<0.05).The side effects of Mifpriston were significant lower than Gestrinone's.Conclusion:Depot Mifepriston seems to be an effective,safe, and convenient treatment for ovary endometriosis with low-cost and few side effects.Then it can be used medication after surgery.